NEW YORK (GenomeWeb) – IncellDx today announced it received CE marking for it flow cytometry-based test for human papillomavirus.

The company also announced the launch of the test, which combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay. It quantifies the E6/E7 mRNA overexpression by RNA in situ hybridization and combines it with cell cycle DNA, which quantifies proliferation, which IncellDx said is a hallmark of transformation to cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.